• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Executive Officer O'Heeron Pete bought $16,269 worth of shares (8,500 units at $1.91), increasing direct ownership by 0.14% to 6,056,647 units (SEC Form 4)

    8/12/24 9:58:49 PM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FBLG alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    O'HEERON PETE

    (Last) (First) (Middle)
    C/O FIBROBIOLOGICS, INC.
    455 E. MEDICAL CENTER BLVD. SUITE 300

    (Street)
    HOUSTON TX 77598

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    FibroBiologics, Inc. [ FBLG ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Executive Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    08/12/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 08/12/2024 P 8,500 A $1.914(1) 6,056,647 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiples transactions ranging from $1.82 to $2.017 on August 12, 2024. The reporting person will provide upon request to the SEC, the issuer, or security holder of the Issuer, full information regarding the number of shares purchased at each separate price.
    /s/ Ruben A. Garcia, by Power of Attorney 08/12/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $FBLG alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FBLG

    DatePrice TargetRatingAnalyst
    12/12/2024$12.00Buy
    Rodman & Renshaw
    10/30/2024$12.00Buy
    H.C. Wainwright
    9/24/2024$12.00Buy
    Maxim Group
    More analyst ratings

    $FBLG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    HOUSTON, July 31, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced second quarter 2025 financial results and provided a corporate update. Recent Highlights Successfully closed third $5 million tranche of a $25 million total financing, with proceeds used to advance research and development efforts and support the upcoming Phase 1/2 clinical trial in diabetic foot ulcers (DFUs).Strengthened leadership team with the appointment of

    7/31/25 4:30:00 PM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications

    HOUSTON, July 28, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the filing of a patent application with the United States Patent and Trademark Office covering methods of generating multipotent cells from fibroblasts found in donor tissue for clinical applications. Multipotency refers to a flexible cellular state in which a cell has the potential to differentiate into multiple specialized cell types, depending on the environmental co

    7/28/25 8:30:00 AM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FibroBiologics to Present at the Advanced Wound Care Summit USA

    HOUSTON, July 11, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O'Heeron, will present at the Advanced Wound Care Summit USA in Boston, Massachusetts, on July 15, 2025. The presentation will include recent research advances using fibroblast-based technology for indications such as wound healing and psoriasis. "The Advanced Wound Care Summit is an ideal forum to showcase how FibroB

    7/11/25 8:30:00 AM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FBLG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Niklas Victoria Ninon Olivia

    4 - FibroBiologics, Inc. (0001958777) (Issuer)

    6/12/25 7:30:37 PM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Link Matthew

    4 - FibroBiologics, Inc. (0001958777) (Issuer)

    6/12/25 7:26:50 PM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Hoffman Robert E.

    4 - FibroBiologics, Inc. (0001958777) (Issuer)

    6/12/25 7:23:52 PM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FBLG
    SEC Filings

    View All

    FibroBiologics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - FibroBiologics, Inc. (0001958777) (Filer)

    8/8/25 4:05:27 PM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by FibroBiologics Inc.

    10-Q - FibroBiologics, Inc. (0001958777) (Filer)

    7/31/25 4:15:51 PM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: FibroBiologics Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities

    8-K/A - FibroBiologics, Inc. (0001958777) (Filer)

    7/18/25 4:08:05 PM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FBLG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Scientific Officer Khoja Hamid bought $16,800 worth of shares (20,000 units at $0.84), increasing direct ownership by 178% to 31,250 units (SEC Form 4)

    4 - FibroBiologics, Inc. (0001958777) (Issuer)

    5/27/25 5:56:53 PM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer O'Heeron Pete bought $16,269 worth of shares (8,500 units at $1.91), increasing direct ownership by 0.14% to 6,056,647 units (SEC Form 4)

    4 - FibroBiologics, Inc. (0001958777) (Issuer)

    8/12/24 9:58:49 PM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Scientific Officer Khoja Hamid bought $19,000 worth of shares (10,000 units at $1.90), increasing direct ownership by 800% to 11,250 units (SEC Form 4)

    4 - FibroBiologics, Inc. (0001958777) (Issuer)

    8/12/24 9:58:39 PM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FBLG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rodman & Renshaw initiated coverage on FibroBiologics with a new price target

    Rodman & Renshaw initiated coverage of FibroBiologics with a rating of Buy and set a new price target of $12.00

    12/12/24 8:54:24 AM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on FibroBiologics with a new price target

    H.C. Wainwright initiated coverage of FibroBiologics with a rating of Buy and set a new price target of $12.00

    10/30/24 6:37:36 AM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group initiated coverage on FibroBiologics with a new price target

    Maxim Group initiated coverage of FibroBiologics with a rating of Buy and set a new price target of $12.00

    9/24/24 7:59:12 AM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FBLG
    Leadership Updates

    Live Leadership Updates

    View All

    FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    HOUSTON, July 31, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced second quarter 2025 financial results and provided a corporate update. Recent Highlights Successfully closed third $5 million tranche of a $25 million total financing, with proceeds used to advance research and development efforts and support the upcoming Phase 1/2 clinical trial in diabetic foot ulcers (DFUs).Strengthened leadership team with the appointment of

    7/31/25 4:30:00 PM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial Officer

    HOUSTON, June 09, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the appointment of Jason D. Davis, CPA, as Chief Financial Officer, effective immediately. Mr. Davis brings extensive experience in corporate finance, capital markets, and SEC reporting, with a proven track record of successfully leading companies through critical growth phases, including IPOs and capital raising initiatives. His appointment comes as FibroBiologic

    6/9/25 8:30:00 AM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FibroBiologics Set to Join Russell 2000® Index

    HOUSTON, June 13, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced today it is set to join the Russell 2000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30, ranking them b

    6/13/24 9:31:00 AM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care